Mycophenolate Mofetil: An Overview

Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005; 14: S2–S8.

The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1997; 61: 1029–1037.

Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225–232.

Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715–2729.

Moder KG. Mycophenolate mofetil: new applications for this immunosuppressant. Ann Allergy Asthma Immunol 2003; 90: 15–19.

Briggs WA , Choi MJ , Scheel PJ Jr . Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998; 31: 213–217.

Chan TM , Li FK , Tang CS Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156–1162.

Hu W , Liu Z , Chen H Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002; 115: 705–709.

Ginzler EM , Dooley MA , Aranow C Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219–2228.

Ong LM , Hooi LS , Lim TO Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005; 10: 504–510.

Contreras G , Pardo V , Leclercq B Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971–980.

Ye ZZ , Tan YH , Hong XP MMF versus CTX in the treatment of severe SLE patients. Lupus 2001; 10: S99.

Florez-Suarez LF , Villa AR. Preliminary results of an open randomised clinical trial comparing mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IV-CYC) as induction therapy for severe lupus nephritis (LN). Arth Rheum 2004; 50: S415.

Chan TM , Tse KC , Tang CS Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1–9.

Cross J , Dwomoa A , Andrews P Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 2005; 100: c92–c100.

Pisoni CN , Sanchez FJ , Karim Y Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005; 32: 1047–1052.

Riskalla MM , Somers EC , Fatica RA , McCune WJ. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1508–1512.

Sinclair A , Appel G , Dooley MA Protocol for the Aspreva Lupus Management Study. J Am Soc Nephrol 2005; 16: 528A.

Aspreva Lupus Management Study (ALMS). ClinicalTrials.gov (NCT00121082). http://www.clinicaltrials.gov, accessed 28 May 2006.

Mycophenolate Mofetil versus azathioprine for maintenance therapy of lupus nephritis. ClinicalTrials.gov (NCT00204022). http://www.clinicaltrials.gov, accessed 28 May 2006.

Comparison of short course cyclophosphamide followed by mycophenolate mofetil versus long course cyclophosphamide in the treatment of proliferative lupus nephritis. Current Controlled Trials (ISRCTN34634478), http://www.controlled-trials.com, accessed 28 May 2006.

Moder GK , Mazlumzadeh M , Amin S , Ytterberg SR. Use of mycophenolate mofetil in non-renal lupus. Arth Rheum 2004; 50: S415.

Pisoni CN , Karim Y , Cuadrado MJ. Myconphenolate mofetil and systemic lupus erythematosus: an overview. Lupus 2005; 14(Suppl 1): S9–S11.

Karim MY , Abbs IC. Mycophenolate mofetil in nonlupus glomerulonephropathy. Lupus 2005; 14(Suppl 1): S39–S41.

D'Cruz DP. Mycophenolate mofetil in systemic vasculitis. Lupus 2005; 14(Suppl 1); S55–S57.

Mycophenolate mofetil for treatment of relapses of Wegener's Disease or microscopic polyangiitis (MPA). ClinicalTrials.gov (NCT00103792). http://www.clinicaltrials.gov, accessed 28 May 2006.

Mycophenolate mofetil (MMF) in patients with IgA nephropathy. ClinicalTrials.gov (NCT00318474). http://www.clinicaltrials.gov, accessed 28 May 2006.

Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT). ClinicalTrials.gov (NCT00135811). http://www.clinicaltrials.gov, accessed 3 June 2006.

IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis. ClinicalTrials.gov (NCT00307645). http://www.clinicaltrials.gov, accessed 7 June 2006.

Cahoon WD Jr Kockler DR. Mycophenolate mofetil treatment of myasthenia gravis. Ann Pharmacother 2006; 40: 295–298.

Ciafaloni E. Mycophenolate mofetil and myasthenia gravis. Lupus 2005; 14(Suppl 1); S46–S49.

Trial of mycophenolate mofetil in myasthenia gravis. ClinicalTrials.gov (NCT00127894). http://www.clinicaltrials.gov, accessed 28 May 2006.

Adjunct CellCept (mycophenolate mofetil) with reduced corticosteroids in subjects with myathenia gravis. ClinicalTrials.gov (NCT00090636). http://www.clinicaltrials.gov, accessed 28 May 2006.

Hartmann M , Enk A. Mycophenolate mofetil and skin diseases. Lupus 2005; 14: S58–S63.

CellCept® (mycophenolate mofetil) in pemphigus vulgaris. ClinicalTrials.gov (NCT00140127). http://www.clinicaltrials.gov, accessed 28 May 2006.

Urowitz MB , Bookman AA , Koehler BE The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221–225.

Manzi S , Meilahn EN , Rairie JE Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408–415.

Schattner A , Liang MH. The cardiovascular burden of lupus: a complex challenge. Arch Intern Med 2003; 163: 1507–1510.

Roman MJ , Shanker BA , Davis A Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399–2406.

Asanuma Y , Oeser A , Shintani AK Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407–2415.

Lima DS , Sato EI , Lima VC Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 292–297.

Johnson SR , Harvey PJ , Floras JS Impaired brachial artery endothelium dependent flow mediated dilation in systemic lupus erythematosus: preliminary observations. Lupus 2004; 13: 590–593.

Bruce IN , Urowitz MB , Gladman DD Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arth Rheum 2003; 48: 3159–3167.

Bruce IN , Urowitz MB , Gladman DD , Hallett DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26: 2137–2143.

Fisher LM , Schlienger RG , Matter C Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93: 198–200.

Esdaile JM , Abrahamowicz M , Grodzicky T Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arth Rheum 2001; 44: 2331–2337.

Bruce IN. ‘Not only … but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005; 44: 1492–1502.

Nuttall SL , Heaton S , Piper MK Cardiovascular risk in systemic lupus erythematosus - evidence of increased oxidative stress and dyslipidaemia. Rheumatology 2003; 42: 758–762.

McMahon M , Grossman J , Fitzgerald J Pro-inflammatory HDL as a biomarker for atherosclerosis for SLE and RA. Arth Rheum 2005; 55: S697.

Reiss AB , Awadallah NW , Malhotra S Immune complexes and IFN-γ decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J Lipid Res 2001; 42: 1913–1922.

Boey ML , Colaco CB , Gharavi AE Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed) 1983; 287: 1021–1023.

Vaarala O , Mänttäri M , Manninen V Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23–27.

Wu R , Nityanand S , Berglund L Antibodies against cardiolipin and oxidatively modified ldl in 50-year-old men predict myocardial infarction. Arterioscler Throm Vasc Biol 1997; 17: 3159–3163.

Svenungsson E , Jensen-Urstad K , Heimbürger M Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887–1893.

Selzer F , Sutton-Tyrrell K , Fitzgerald SF Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arth Rheum 2004; 50: 151–159.

Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003; 349: 2379–2380.

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–1695.

van Leuven SI , Kastelein JJ , Allison AC Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles? Cardiovasc Res 2005; 69: 341–347.

Utimura R , Fujihara CK , Mattar AL Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003; 63: 209–216.

Ross R. Atherosclerosis - an inflammatory disease. New Engl J Med 1999; 340: 115–126.

Shimizu H , Takahashi M , Takeda S Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle profileration. Transplantation 2004; 77: 1661–1667.

Raisanen-Sokolowski A , Vuoristo P , Myllarmiemi M Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl Immunol 1995; 3: 342–351.

Boots JM , Christiaans MH , van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004; 64: 2047–2073.

Vanrenterghem Y. Anaemia after renal transplantation. Nephrol Dial Transplant 2004; 19(Suppl 5): V54–V58.

Winkelmayer WC , Kewalramani R , Rutstein M Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol 2004; 15: 1347–1352.

Fernandez Fresnedo G , Palomar R , Rodrigo E Prevalence of anemia in renal transplant patients: results from MOST, an observational trial. Transplant Proc 2005; 37: 3821–3822.

Mak A , Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 2005; 14: 856–858.

Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84: 985–992.

Li S , Foley RN , Collins AJ. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol 2005; 37: 395–402.

Eisen HJ , Kobashigawa J , Keogh A Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 517–525.

Schnitzler MA , Craig KE , Hardinger KE Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation. Nephrol Dial Transplant 2003; 18: 1197–1200.

David KM , Morris JA , Steffen BJ Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant 2005; 19: 279–285.

Hosenpud JD , Bennett LE. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation 2001; 72: 1662–1665.

Kobashigawa J , Miller L , Renlund D A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66: 507–515.

Kobashigawa JA , Tobis JM , Mentzer RM Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant 2006; 6: 993–937.

A prospective, randomised, double-blind, placebo-controlled trial evaluating the effects of mycophenolate mofetil (MMF) on surrogate markers for atherosclerosis in female patients with systemic lupus erythematosus. Current Controlled Trials (ISRCTN57744970). http://www.controlled-trials.com, accessed 28 May 2006.

Hardinger KL , Brennan DC , Lowell J , Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004; 17: 609–616.

Tierce JC , Porterfield-Baxa J , Petrilla AA Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005; 19: 779–784.

Maes BD , Dalle I , Geboes K Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 2003; 75: 665–672.

Dalle IJ , Maes BD , Geboes KP Crohn's-like changes in the colon due to mycophenolate? Colorectal Dis 2005; 7: 27–34.

Papadimitriou JC , Cangro CB , Lustberg A Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int J Surg Pathol 2003; 11: 295–302.

Kang I , Park SH. Infectious complications in SLE after immunosuppressive therapies. Current Opin Rheumatol 2003; 15: 528–534.

Trager J , Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001; 13: 345–351.

Bernatsky S , Ramsey-Goldman R , Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol 2006; 18: 129–134.

Zintzaras E , Voulgarelis M , Moutsopoulos HM. The risk of lymphoma development in autoimmune disease: a meta-analysis. Arch Intern Med 2005; 165: 2337–2344.

Kasiske BL , Snyder JJ , Gilbertson DT , Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905–913.

Funch DP , Koh HH , Travasso J Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation 2005; 80: 1174–1180.

Robson R , Cecka JM , Opelz G Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954–2960.

Dasgupta N , Gelber AC , Racke F , Fine DM. Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus 2005; 14: 910–913.

Edge JC , Outland JD , Dempsey JR , Callen JP. Mycophenolate mofetil is an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006; 142: 65–69.

Vernino S , Salomao DR , Habermann TM , O'Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 2005; 65: 639–641.

Briggs WA , Choi MJ , Scheel PJ. Follow-up on mycophenolate treatment of glomerular disease. Am J Kidney Dis 1998; 31: 898–899.

Katsifis GE , Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 2004; 13: 673–678.

Fine DM. Pharmacological therapy of lupus nephritis. JAMA 2005; 293: 3053–3060.

Roche Laboratories Inc. CellCept® US package insert, revised October 2005.

Le Ray C , Coulomb A , Elefant E Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 2004; 103: 1091–1094.

Pergola PE , Kancharla A , Riley DJ. Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation 2001; 71: 994–997.

EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Longterm management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant 2002; 17(Suppl 4): 50–55.